[HTML][HTML] Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy
Despite compelling rates of durable clinical responses to programmed cell death-1 (PD-1)
blockade, advances are needed to extend these benefits to resistant tumors. We found that …
blockade, advances are needed to extend these benefits to resistant tumors. We found that …
[HTML][HTML] Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy
MT Chow, AJ Ozga, RL Servis, DT Frederick, JA Lo… - Immunity, 2019 - Elsevier
Despite compelling rates of durable clinical responses to programmed cell death-1 (PD-1)
blockade, advances are needed to extend these benefits to resistant tumors. We found that …
blockade, advances are needed to extend these benefits to resistant tumors. We found that …
[引用][C] Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy
MT Chow, AJ Ozga, RL Servis, DT Frederick, JA Lo… - Immunity, 2019 - cir.nii.ac.jp
Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1
Therapy | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
Therapy | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy
MT Chow, AJ Ozga, RL Servis, DT Frederick… - …, 2019 - pubmed.ncbi.nlm.nih.gov
Despite compelling rates of durable clinical responses to programmed cell death-1 (PD-1)
blockade, advances are needed to extend these benefits to resistant tumors. We found that …
blockade, advances are needed to extend these benefits to resistant tumors. We found that …
[HTML][HTML] Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy
MT Chow, AJ Ozga, RL Servis, DT Frederick, JA Lo… - Immunity, 2019 - ncbi.nlm.nih.gov
Despite compelling rates of durable clinical responses to PD-1 blockade, advances are
needed to extend these benefits to resistant tumors. We found that tumor-bearing mice …
needed to extend these benefits to resistant tumors. We found that tumor-bearing mice …
Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy.
MT Chow, AJ Ozga, RL Servis, DT Frederick, JA Lo… - Immunity, 2019 - europepmc.org
Despite compelling rates of durable clinical responses to PD-1 blockade, advances are
needed to extend these benefits to resistant tumors. We found that tumor-bearing mice …
needed to extend these benefits to resistant tumors. We found that tumor-bearing mice …
Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy.
MT Chow, AJ Ozga, RL Servis, DT Frederick, JA Lo… - Immunity, 2019 - europepmc.org
Despite compelling rates of durable clinical responses to PD-1 blockade, advances are
needed to extend these benefits to resistant tumors. We found that tumor-bearing mice …
needed to extend these benefits to resistant tumors. We found that tumor-bearing mice …